Leukapheresis and Hyperleukocytosis, Past and Future.
Dongdong ZhangYufan ZhuYanxia JinNatasha Mupeta KawemeYouhong DongPublished in: International journal of general medicine (2021)
Hyperleukocytosis is a hematologic crisis caused by excessive proliferation of leukemic cells and has a relatively high early mortality due to a series of severe complications. Therefore, prompt and effective intervention is required. Leukapheresis performed using apheresis equipment to separate leukocytes from peripheral blood, at the same time returns autologous plasma, platelets and erythrocytes to the patient, is applied clinically for the treatment of hyperleukocytosis. Leukapheresis not only removes excessive leukocytes rapidly and corrects metabolic abnormalities but also alleviates the symptoms of leukostasis. In addition, the procedure of leukapheresis is generally well tolerated. Leukapheresis has become one of the most imperative adjuvant therapies to treat hyperleukocytosis, especially in the patient who was not inappropriate to cytoreduce with Ara-C or hydroxyurea. In this review, we present the background of leukapheresis development and highlight its clinical application in hyperleukocytic leukemia patients.
Keyphrases
- peripheral blood
- end stage renal disease
- acute myeloid leukemia
- case report
- induced apoptosis
- bone marrow
- newly diagnosed
- ejection fraction
- weight gain
- public health
- chronic kidney disease
- signaling pathway
- prognostic factors
- cardiovascular events
- peritoneal dialysis
- type diabetes
- early stage
- mouse model
- body mass index
- current status
- oxidative stress
- cell therapy
- depressive symptoms
- cardiovascular disease
- cell proliferation
- drug induced
- physical activity
- stem cells
- pi k akt
- cell death
- patient reported outcomes